NCT07413913

A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like Injector

Bioequivalence of Survodutide (BI 456906) When Administered Via Pre-filled Syringe (Formulation A) and Pre Filled Pen (Formulation B2) in Male and Female Trial Participants Who Are Healthy or Otherwise Healthy With Overweight/Obesity (an Open-label, Randomised, Single-dose, Two-period, Two-sequence Crossover Trial)

• Status: Active Not Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 56 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The goal of this study is to find out whether different formulations of survodutide given by different delivery methods is taken up in the body in a similar way. Participants visit the study site regularly. During study visits, the doctors collect information about participants' health. To assess the study endpoints, participants regularly have blood samples taken.

Conditions

• Healthy
• Obesity

Interventions

Type	Name	Description
COMBINATION_PRODUCT	Survodutide formulation A	Pre-filled syringe
COMBINATION_PRODUCT	Survodutide formulation B2	Pre-filled pen

Timeline

• Start date: 2026-03-03
• Primary completion: 2026-05-28
• Completion: 2026-06-08
• First posted: 2026-02-17
• Last updated: 2026-04-17

Locations

1 site across 1 country: Germany

Regulatory

• FDA-regulated drug study